Bevorzugter Name Reltecimod
IUPAC (3S)-3-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2R)-2-aminopropanoyl]amino]-3-hydroxypropanoyl]pyrrolidine-2-carbonyl]amino]-4-methylsulfanylbutanoyl]amino]-4-methylpentanoyl]amino]-3-methylbutanoyl]amino]propanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[[(1R)-1-carboxyethyl]amino]-4-oxobutanoic acid
Englischer Name Reltecimod
Summenformel C46H72N10O15S
Molmasse 1037.2 Namen und Synonyme Reltecimod 1447799-33-8 AB103 U00J02UY29 D-Alanine, D-alanyl-L-seryl-L-prolyl-L-methionyl-L-leucyl-L-valyl-L-alanyl-L-tyrosyl-L-alpha-aspartyl- D-ALANYL-L-SERYL-L-PROLYL-L-METHIONYL-L-LEUCYL-L-VALYL-L-ALANYL-L-TYROSYL-L-ASPARTYL-D-ALANINE reltecimodum p2TA peptide AB103 peptide SPMLVAYD RefChem:930642 D-Alanyl-(t-cell-specific surface glycoprotein CD28-(8-15)-peptide)-D-alanine:D-alanyl-L-seryl-L-prolyl-L-methionyl-L-leucyl-L-valyl-L-alanyl-L-tyrosyl-L-alpha-aspartyl-D-alanine immunomodulator
Weitere Namen anzeigen P-2TA Reltecimod (peptide) D-Alanine, D-alanyl-L-seryl-L-prolyl-L-methionyl-L-leucyl-L-valyl-L-alanyl-L-tyrosyl-L-α-aspartyl-
Reltecimod [INN] Reltecimod [USAN] (3S)-3-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2R)-2-aminopropanoyl]amino]-3-hydroxypropanoyl]pyrrolidine-2-carbonyl]amino]-4-methylsulfanylbutanoyl]amino]-4-methylpentanoyl]amino]-3-methylbutanoyl]amino]propanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[[(1R)-1-carboxyethyl]amino]-4-oxobutanoic acid (5S,8S,11S,14S,17S,20S,23R)-5-((S)-1-((S)-2-((R)-2-Aminopropanamido)-3-hydroxypropanoyl)pyrrolidine-2-carboxamido)-20-(carboxymethyl)-17-(4-hydroxybenzyl)-8-isobutyl-11-isopropyl-14,23-dimethyl-6,9,12,15,18,21-hexaoxo-2-thia-7,10,13,16,19,22-hexaazatetracosan-24-oic acid p2TA Reltecimod [WHO-DD] Reltecimod (USAN/INN) Reltecimod [USAN:INN]
Mehr laden (20 angezeigt)